Kairos Pharma (KAPA) Other financing activities (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Other financing activities came in at $3.1 million in Q1 2025, up 3335.96% YoY from $89000.0 in Q1 2024, and down 40.44% on a QoQ basis from $5.1 million in Q4 2024.
Kairos Pharma (KAPA) Other financing activities (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Other financing activities data on file, last reported at $3.1 million in Q1 2025.
- Quarterly Other financing activities rose 3335.96% year-over-year to $3.1 million in Q1 2025, while the trailing twelve-month figure through Jun 2025 was $8.2 million (changed N/A YoY) and the FY2025 annual result came in at $3.1 million, down 44.64% from the prior year.
- Other financing activities retreated to $3.1 million in Q1 2025, from $5.1 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $5.1 million in Q4 2024 to a low of -$47000.0 in Q2 2024.
- A 3-year average of $1.4 million and a median of $80500.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities jumped 7030.56% — and 2025, when it surged 3335.96%.
- Tracing KAPA's Other financing activities over 3 years: stood at $72000.0 in 2023, then jumped by 7030.56% to $5.1 million in 2024, then plunged by 40.44% to $3.1 million in 2025.
- The last three Other financing activities figures came in at $3.1 million (Q1 2025), $5.1 million (Q4 2024), and $34000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 3.06 Mn |
| Mar 31, 2025 | 3.06 Mn |
| Dec 31, 2024 | 5.13 Mn |
| Dec 31, 2024 | 5.13 Mn |
| Sep 30, 2024 | 34,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Jun 30, 2024 | -47,000.00 |
| Jun 30, 2024 | -47,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |